TranS1 Appoints Mark Stautberg to Board of Directors

TranS1 Appoints Mark Stautberg to Board of Directors

WILMINGTON, N.C., Feb. 19, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON),
a medical device company focused on designing, developing and marketing spine
products to treat degenerative conditions of the spine affecting the lumbar
region, announced today that it has appointed Mark Stautberg to serve on its
Board of Directors. Mr. Stautberg has over thirty years of experience in
management and sales in the medical device industry.

"Mark brings significant experience in executive sales management of medical
devices including new product launches," stated Ken Reali, President and CEO
of TranS1 Inc. "We believe Mark's background will provide the board with
valuable perspective as we enter an important growth period and continue to
strengthen our direct sales force and strategy."

Mr. Stautberg, 53, currently serves as a sales and marketing consultant for
multiple medical device companies.From 2004 to 2012, he served as a
consultant to Boston Scientific Corporation's Cardio Rhythm Vascular
Division.Prior to his service as a consultant, Mr. Stautberg was employed by
Boston Scientific's Cardiovascular Division, serving as Senior Vice President
of Sales from 1998 to 2004 and in other positions from 1991 to 1998.Mr.
Stautberg previously served on the board of directors and as a consultant of
Sealing Solutions, Inc., a vascular sealing company, from 2007 to 2010 and
FlowCardia, Inc., a chronic total occlusion device company, from 2004 to
2010.Mr. Stautberg received a B.B.A. degree from the University of Cincinnati
and has completed executive programs at Columbia University.

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and
marketing products to treat degenerative conditions of the spine affecting the
lumbar region. TranS1 currently markets the AxiaLIF® family of products for
single and two level lumbar fusion, the VEO^TM lateral access and interbody
fusion system and the Vectre^TM posterior fixation system for lumbar fixation
supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is
headquartered in Wilmington, North Carolina. For more information, visit
www.trans1.com.

CONTACT: Investors:
         TranS1 Inc.
         Joe Slattery, 910-332-1700
         Executive Vice-President and Chief Financial Officer
        
         or
        
         Westwicke Partners
         Mark Klausner, 443-213-0501
         mark.klausner@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.